Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reissued by stock analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Separately, HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, January 10th.

60 Degrees Pharmaceuticals Stock Performance

Shares of NASDAQ SXTP opened at $0.62 on Friday. 60 Degrees Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $7.20. The company has a market cap of $1.43 million, a price-to-earnings ratio of -0.06 and a beta of 4.24. The business’s 50 day moving average price is $1.16 and its 200-day moving average price is $1.07.

Insider Activity

In other news, CEO Geoffrey S. Dow acquired 35,823 shares of the business’s stock in a transaction on Monday, December 9th. The stock was bought at an average price of $1.27 per share, with a total value of $45,495.21. Following the completion of the acquisition, the chief executive officer now owns 94,580 shares of the company’s stock, valued at approximately $120,116.60. This represents a 60.97 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have acquired 66,372 shares of company stock valued at $82,410 in the last ninety days. Insiders own 10.27% of the company’s stock.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.